(Q74820371)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

title

Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference

1 reference

1 reference

T Sugiyama

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

M Yakushiji

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

T Nishida

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

K Ushijima

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

N Okura

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

J Kigawa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

N Terakawa

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

language of work or name

English

0 references

publication date

1 June 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

volume

128

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

page(s)

211-218

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

13 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Evidence for an intermediate with a single-strand break in the reaction catalyzed by the DNA untwisting enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Treatment of recurrent gynaecologic malignancies with a new camptothecin derivative

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Effects of CPT-11 in combination with other anti-cancer agents in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Confidence intervals for reporting results of clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0304-3835%2898%2900065-2

7 January 2021

10.1016/S0304-3835(98)00065-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9683285%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference